We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

547 hedge funds and large institutions have $18B invested in BioMarin Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 85 funds opening new positions, 178 increasing their positions, 207 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 85 | Existing positions closed: 50

36% more call options, than puts

Call options by funds: $193M | Put options by funds: $141M

12% more capital invested

Capital invested by funds: $16.1B → $18B (+$1.96B)

5% more funds holding

Funds holding: 519 → 547 (+28)

2.79% more ownership

Funds ownership: 96.45% → 99.24% (+2.8%)

0% more funds holding in top 10

Funds holding in top 10: 14 → 14 (0)

14% less repeat investments, than reductions

Existing positions increased: 178 | Existing positions reduced: 207

Holders
547
Holders Change
+28
Holders Change %
+5.39%
% of All Funds
7.97%
Holding in Top 10
14
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.2%
New
85
Increased
178
Reduced
207
Closed
50
Calls
$193M
Puts
$141M
Net Calls
+$51.4M
Net Calls Change
-$924K

Top Buyers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
+$421M
2
EIM
Elliott Investment Management
Florida
+$265M
3
Deutsche Bank
Deutsche Bank
Germany
+$177M
4
Morgan Stanley
Morgan Stanley
New York
+$99M
5
Millennium Management
Millennium Management
New York
+$80M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$337M
2
Nomura Holdings
Nomura Holdings
Japan
-$62.6M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$56.1M
4
Pictet Asset Management
Pictet Asset Management
Switzerland
-$44.7M
5
PHS
PFM Health Sciences
California
-$44.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIC
501
Archer Investment Corporation
Indiana
$6.75K – – –
CJ
502
Caitlin John
Michigan
$6.36K +$5.84K +66 New
NS
503
NBC Securities
Alabama
$6K – – –
OLVIG
504
Oliver Lagore Vanvalin Investment Group
Michigan
$4.82K – – –
CFO
505
CVA Family Office
Colorado
$4.82K +$4.42K +50 New
GWS
506
Glassman Wealth Services
Virginia
$4.15K -$14.2K -160 -79%
RFG
507
RFP Financial Group
Georgia
$4.15K – – –
BTI
508
Blue Trust Inc
Georgia
$4K +$265 +3 +7%
WIA
509
Wetzel Investment Advisors
Indiana
$4K +$3.63K +41 New
FFO
510
Fortitude Family Office
Arizona
$3.95K +$3.63K +41 New
RL
511
Rogco LP
Oklahoma
$3.66K – – –
UB
512
UMB Bank
Missouri
$3.66K – – –
MA
513
Montag & Associates
Georgia
$3.28K – – –
FMP
514
Financial Management Professionals
Texas
$3K – – –
CSC
515
Caldwell Sutter Capital
California
$2.99K – – –
LF
516
Lee Financial
Texas
$2.89K – – –
PCFFS
517
Pacific Center for Financial Services
California
$2.89K – – –
FGAM
518
Financial Gravity Asset Management
Texas
$2.74K +$1.15K +13 +100%
HFM
519
Hartford Financial Management
Connecticut
$2.7K – – –
SA
520
Scarborough Advisors
Maryland
$2.6K +$2.39K +27 New
VCM
521
Versant Capital Management
Arizona
$2.22K +$531 +6 +35%
S
522
Sachetta
Massachusetts
$2.22K +$2.04K +23 New
RA
523
Rise Advisors
New York
$2.12K – – –
BIA
524
Bell Investment Advisors
California
$2.02K -$1.42K -16 -43%
ZB
525
Zions Bancorporation
Utah
$2.02K – – –
19 20
21
22 23

BMRN Hedge Fund Activity: Q4 2023 in Review

547 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2023, worth a combined $18B — up 12% from $16.1B a quarter earlier.

Buyers outnumbered sellers: 85 funds opened new BMRN positions and 50 closed out — a net gain of 35 holders — while 178 added to existing stakes and 207 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $421M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $337M sold.

  • 547 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2023, up from 519 in Q3 2023.
  • Funds reported $18B of BioMarin Pharmaceuticals stock for Q4 2023, up 12% quarter-over-quarter.
  • 85 funds opened new BioMarin Pharmaceuticals positions in Q4 2023 and 50 closed out, a net change of +35 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2023 was Capital Research Global Investors, an estimated $421M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2023 was Baker Bros. Advisors, an estimated $337M sold.

Based on aggregated 13F filings for Q4 2023.